Business Context and Reporting Period
This Form 8-K is filed by Organovo Holdings, Inc. (not Vivosim Labs, INC.) on April 2, 2025. The report addresses preliminary unaudited financial results for the fiscal year ending March 31, 2025, and the fourth quarter of 2025. The primary focus is the Company's compliance with Nasdaq listing requirements following a recent asset sale and capital raising activities.
Key Financial Metrics
- Asset Sale Proceeds: The Company sold its FXR program and related assets to Eli Lilly and Company for an upfront cash payment of $10.0 million ($9.0 million paid at closing; $1.0 million in escrow).
- Stockholders' Equity: As of April 2, 2025, the Company believes it has achieved a minimum of $2,500,000 in stockholders' equity, meeting the Nasdaq minimum requirement.
- Prior Equity Status: As of December 31, 2024, stockholders' equity was reported at $364,000, which was below the $2.5 million threshold.
- Revenue and Profit: The filing text does not provide specific revenue, net income, or profit margin figures for the fiscal year or quarter, only referencing "anticipated losses to date."
- Cash Flow: Specific cash flow metrics are not detailed in the text, though the filing notes "net cash utilization results" were reported in an attached press release.
Material Changes
- Asset Disposition: On March 25, 2025, the Company completed the sale of its FXR program to Eli Lilly, generating significant liquidity.
- Capital Raising: The Company conducted warrant exercises and sales of common stock under an "at the market" offering to bolster equity.
- Equity Recovery: Stockholders' equity increased from $364,000 (Q4 2024) to an estimated $2.5 million (April 2, 2025) due to the asset sale and capital raises.
Guidance, Outlook, and Risks
- Nasdaq Compliance: The Company expects to meet all requirements for continued listing on the Nasdaq Capital Market. A Hearings Panel granted an exception until April 15, 2025 to demonstrate compliance with the minimum bid price ($1.00) and stockholders' equity ($2.5 million) rules.
- Future Milestones: The asset sale agreement includes potential milestone payments of up to $50.0 million, contingent on development, regulatory, and commercial achievements.
- Risks: There is no assurance the Company will maintain compliance with Nasdaq bid price or equity requirements in the future. The preliminary financial data is unaudited and subject to adjustment.
Investor Verification Checklist
- Verify the final audited stockholders' equity figure in the upcoming Form 10-K to confirm the $2.5 million threshold is met.
- Monitor the Company's stock price to ensure it maintains the $1.00 minimum bid price required by Nasdaq Rule 5550(a)(2).
- Review the attached Press Release (Exhibit 99.1) for specific details on net cash utilization and quarterly losses not included in this summary.
- Track the status of the $1.0 million escrow held by Eli Lilly and the conditions for the $50.0 million in potential milestone payments.